Leerink Partnrs Predicts Weaker Earnings for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Exact Sciences in a report released on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.06). The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences' Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at $0.20 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million.

Several other brokerages also recently issued reports on EXAS. Scotiabank raised their price target on Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. Bank of America lowered their target price on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Guggenheim reaffirmed a "buy" rating and issued a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. Piper Sandler reduced their price objective on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Benchmark reaffirmed a "buy" rating and set a $65.00 target price on shares of Exact Sciences in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $69.25.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $44.15 on Wednesday. The firm has a market capitalization of $8.20 billion, a PE ratio of -7.93 and a beta of 1.14. Exact Sciences has a 1 year low of $39.97 and a 1 year high of $72.83. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The firm's fifty day simple moving average is $45.60 and its 200 day simple moving average is $54.62.

Institutional Investors Weigh In On Exact Sciences

Several large investors have recently made changes to their positions in EXAS. Thompson Investment Management Inc. boosted its position in Exact Sciences by 17.8% in the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock valued at $13,585,000 after buying an additional 36,505 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Exact Sciences by 35.3% in the 4th quarter. Harbor Capital Advisors Inc. now owns 95,827 shares of the medical research company's stock worth $5,385,000 after acquiring an additional 24,992 shares in the last quarter. Jones Financial Companies Lllp grew its position in Exact Sciences by 32.2% during the 4th quarter. Jones Financial Companies Lllp now owns 9,508 shares of the medical research company's stock worth $534,000 after acquiring an additional 2,315 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Exact Sciences during the 4th quarter valued at $478,000. Finally, Sanctuary Advisors LLC raised its position in Exact Sciences by 2.0% in the 4th quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company's stock valued at $763,000 after purchasing an additional 269 shares during the last quarter. Institutional investors own 88.82% of the company's stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.